GLP-1s and PCOS: separating real benefits from hype

What's this video probably claiming?

Based on the caption and hashtag stack, @drkellylupo is almost certainly celebrating patient results using tirzepatide or semaglutide in women with PCOS and insulin resistance. The "my girls are killin it" framing suggests before/after weight loss results, possibly combined with improvements in hormonal markers or cycle regularity. Creators in this space routinely position GLP-1s as a near-cure for PCOS, pointing to weight loss as the mechanism that fixes everything downstream. The insulin resistance hashtag is a tell: it's the go-to explanatory frame for why these drugs supposedly work so well in PCOS patients specifically, over and above what you'd expect from weight loss alone. That framing is partially supported by data, but the clinical picture is messier than a TikTok caption lets on.

What does the science actually show?

The honest answer is: promising, but nowhere near settled. A 2023 randomized controlled trial by Jensterle et al. in Diabetes, Obesity and Metabolism found that semaglutide 1.0 mg weekly produced significantly greater weight loss and androgen reduction in women with PCOS compared to lifestyle intervention alone over 24 weeks. Tirzepatide data specific to PCOS is thinner. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed up to 20.9% body weight reduction at 72 weeks with tirzepatide 15 mg in adults with obesity, but PCOS wasn't a primary endpoint. Insulin resistance improvement in PCOS likely reflects weight loss more than a direct drug mechanism, per a 2022 meta-analysis by Huang et al. in Frontiers in Endocrinology. These are real effects. They're just not magic, and they don't persist if the medication stops.

Where does the social media noise diverge from clinical reality?

A few places this gets distorted fast. First, "insulin resistance" is used on TikTok as if it's a uniform diagnosis with a clear lab threshold. It isn't. There's no FDA-approved test, no single cutoff, and PCOS-related insulin resistance exists on a spectrum. Second, results like "my girls are killin it" almost never include the patients who dropped out, couldn't tolerate side effects, or plateaued. Publication bias exists in clinical trials; anecdote bias is worse on social media. Third, neither semaglutide nor tirzepatide is FDA-approved specifically for PCOS. Prescribing them for that indication is legal off-label use, but creators often skip that context entirely. And fourth, videos in this category frequently blur the line between compounded GLP-1 formulations and brand-name drugs, which have different manufacturing oversight. Those are not interchangeable claims to make.

What should you actually know?

GLP-1 receptor agonists are genuinely useful tools for some women with PCOS, particularly those with significant obesity and metabolic dysfunction. The weight loss benefit is real, and in women with PCOS, even 5-10% body weight reduction has been associated with improvements in ovulation and androgen levels, per Lim et al. (2019, Human Reproduction Update). But these medications come with real side effect profiles: nausea, vomiting, gastroparesis risk, and rare but serious pancreatitis signals. They require ongoing use to maintain results, and stopping typically reverses weight loss. If you have PCOS and you're considering a GLP-1, the conversation belongs with an endocrinologist or a reproductive medicine specialist who can actually evaluate your full hormonal picture, not a TikTok comment section. Social proof from a creator's patient panel is not a clinical trial.